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ABSTRACT Low DLC1 expression is found to frequently co-occur with aberrant expression of cell cycle
genes including CDK6 in human lung and colon cancer. Here, we explore the inﬂuence of the synergistic
effect of DLC1 and CDK6 on human breast cancer survival at the genetic, transcriptional, and translational
levels. We found that high DLC1 and low CDK6 expression are associated with good prognosis. The DLC1
intronic SNP rs561681 is found to ﬁt a recessive model, complying with the tumor suppressive role of DLC1.
The heterozygote of the DLC1 SNP is found to increase the hazard when the CDK6 intronic SNP rs3731343
is rare homozygous, and it becomes protective when rs3731343 is common homozygous. We propose that
DLC1 expression is the lowest in patients harboring the rare homozygote of rs561681 and functional DLC1
is the lowest when rs561681 is heterozygous and rs3731343 is rare homozygous. We are the ﬁrst to report
such synergistic effects of DLC1 and CDK6 on breast cancer survival at the transcriptional level, the
overdominant model ﬁtted by the SNP pair, and the dominant negative effect at the translational level.
These ﬁndings link the germline genetic polymorphisms and synergistic effect of DLC1 and CDK6 with
breast cancer progression, which provide the basis for experimentally elucidating the mechanisms driving
differential tumor progression and avail in tailoring the clinical treatments for such patients based on their
genetic susceptibility.
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Studies of lung and colon cancer show that underexpression of DLC1
frequently co-occurs with deregulated expression of cell cycle genes
such as CDK6, CDK4, CDKN2A, and CDKN2B. For example, poor
prognosis was reported to be associated with low DLC1, low
CDKN2A/B and high CDK4 in lung cancer, and low DLC1, low
CDKN2B, and high CDK6 in colon cancer (Wu et al. 2009). DLC1,
Deleted in Liver Cancer-1, is a tumor suppressor that is inactivated by
genomic deletions or DNAmethylation in many human malignancies,
including liver, lung, breast, colorectal, and prostate cancer (Qian et al.
2012; Durkin et al. 2007; Kim et al. 2009; Seng et al. 2007). DLC1
catalyses the inactivation of RhoGTP to RhoGDP; however, it is less
efﬁcient in converting Cdc42GTP to Cdc42GDP (Qian et al. 2012).
Rho family GTPases serve as molecular switches in various cellular
functions, including cell cycle progression, cytoskeletal organization,
malignant transformation, cell migration, and cell adhesion to the
extracellular matrix (ECM) (Wu et al. 2009). Reactivation of DLC1 results
in suppression of tumor cell proliferation and reduces tumorigenicity in
liver and colon cancer (Wu et al. 2009; Zhou et al. 2004).
The cyclin-dependent kinases (CDKs) are important regulators of
the mammalian cell cycle (Joyce et al. 2001). CDK4 and CDK6 form
a holoenzyme complex with D cyclins (Pestell et al. 1999; Sherr
1996; Weinberg 1995) to phosphorylate pRB (Matsushime et al.
1991; Kiyokawa et al. 1992; Lukas et al. 1995), leading to the release
of the heterodimeric transcription factor complex, E2F/DP, which
contributes to the transcriptional control of genes that encode cell
cycle regulatory proteins. CDK complexes are subject to regulation
by Ink4 and p21 family proteins (Joyce et al. 2001). Although the p21
family proteins bind and inhibit the activity of cyclin-CDK complexes
under a variety of stress stimuli (Labaer et al. 1997; Cheng et al.
1998), the Ink4 proteins dissociate the cyclinD1/CDK4/6 complex
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(Quelle et al. 1995; Quelle et al. 1997; Pomerantz et al. 1998). CDK4
and CDK6 share 71% amino acid identity (Grossel and Hinds 2006),
are expressed ubiquitously (Meyerson and Harlow 1994; Meyerson
et al. 1992), and function in the G1 phase of the cell cycle (Grossel
and Hinds 2006); thus, they have historically been considered to func-
tion redundantly. Further investigations have revealed that certain types
of tumors selectively amplify either CDK4 or CDK6 (Wolfel et al. 1995;
Timmermann et al. 1997; Zuo et al. 1996; Easton et al. 1998), and they
have distinct subcellular localization (Grossel et al. 1999; Ericson et al.
2003; Mahony et al. 1998; Fahraeus and Lane 1999). Also, CDK6 has
been found to play a role in the differentiation of a variety of cell types
where CDK4 does not (Grossel and Hinds 2006).
Here, we explore the functional relations between DLC1 and
CDK6 in breast cancer survival at both germ line genetic and gene
expression levels. Such interactions were also examined among their
relevant proteins, such as those that directly bind to them at the
translational level. The results help us in understanding the
cooperation between DLC1 and CDK6 in breast cancer, which, once
experimentally veriﬁed, contribute to personalized medicine and can
be applied for clinical use.
MATERIALS AND METHODS
Data
Supporting Information, Table S1 summarizes the major data sets
used in this study, with details shown below.
Genotype data
HEBCS data set: The HEBCS (Helsinki Breast Cancer Study) data were
collected in Helsinki, Finland, and are representative of breast cancer case
series at the recruitment center during the collection periods (unselected
cases collected 1997–1998 and 2000 as well as 2001–2004, with additional
familial cases). All the breast cancer cases included have histopathological
and survival data available; detailed information regarding the patient
series and data collection is available elsewhere (Fagerholm et al. 2008).
The average age at diagnosis is 56.8 years. Genotyping was conducted
using the Illumina 550 platform as previously described (Fagerholm et al.
2008; Li et al. 2011). The intensity data generated were loaded into
Illumina’s Genome studio and genotypes were generated with a GenCall
threshold of 0.15. The data consist of 805 samples.
POSH data set: The POSH (Prospective study of Outcomes in Sporadic
vs. Hereditary breast cancer) data were collected from January 2000 to
January 2008 from oncology clinics in the United Kingdom (Raﬁq et al.
2013). The average age of the participants at diagnosis is 35.5 years.
Genotyping of 543 cases was conducted using the Illumina 660-Quad
SNP array in two separate batches at two locations: 243 triple negative
(ER, PR, and HER2 negative) patients were genotyped at the Mayo
Clinic, Rochester, Minnesota (Haiman et al. 2011) and the rest of the
patients were genotyped at the Genome Institute of Singapore. To ensure
complete harmonization of the genotype calling, the intensity data avail-
able from all locations in form of .idat ﬁles were further combined and
used to generate genotypes based on the algorithm available in the
genotyping module of Illumina’s Genome Studio software. A GenCall
threshold of 0.15 and the HumanHap660 annotation ﬁle were used.
Gene expression data
HEBCS data set: The HEBCS gene expression data (GSE24450) were
used for studying the synergistic effect between genes. There are 183
primary breast tumor samples, among which 151 were collected as
a part of the unselected series at the Department of Oncology of the
Helsinki University Central Hospital (HUCH) in 1997, 1998, and
2000 (Syrjakoski et al. 2000; Kilpivaara et al. 2005) and at the De-
partment of Surgery from 2001 to 2004 (Fagerholm et al. 2008). The
remaining 32 patients belong to an ongoing collection of additional
familial breast cancer series from the department of Clinical Genetics
at HUCH. Data for ER (Estrogen Receptor) status and for PR
(Progesterone Receptor) status were collected from the pathology
reports (Eerola et al. 2005).
Total RNA was extracted from the 183 primary breast tumors,
and the samples were processed and hybridized to Illumina
HumanHT-12_V3 Expression BeadChips containing 24,660 Entrez
Gene entities according to the manufacturer recommendations (http://
www.illumina.com). Gene expression proﬁling was performed at
SCIBLU Genomics Centre, Lund University, Sweden.
Microarray raw data were imported into R (Team 2009) and
processed by the methods included in the BioConductor facilities
(Gentleman et al. 2004; Smyth 2005). Brieﬂy, after quality control (Du
et al. 2008), the data were normalized using the quantile method (Bolstad
et al. 2003) and the gene expression matrix was obtained by averaging
the probes mapped to the same Entrez Gene IDs (Maglott et al. 2005).
TCGA data set: The level 3 primary solid breast tumor mRNA
expression data were retrieved from TCGA (http://cancergenome.nih.
gov) on 21 November 2011 and include 514 samples. The mRNA data
were produced using the Agilent 244K Custom Gene Expression
G4502A-07-3 platform, lowess-normalized, and log2 transformation
of the ratio between two channels was performed.
Protein expression data: The level 2 primary solid breast tumor
reverse-phase protein microarrays (RPPA) data were retrieved from
TCGA on 14 February 2013, and contain 385 samples. The Super
curve log2 values were linearized, median-centered by the median
across all samples, and normalized by the median across the entire
panel of antibodies following the protocol (The University of Texas).
Copy number variation data: Two types of breast cancer copy
number variation (CNV) data, which were log2 transformed copy
number values from Affymetrix SNP6 and putative copy-number calls
determined using GISTIC 2.0 (22, 21, 0, 1, 2 represent homozygous
deletion, hemizygous deletion, neutral, gain, and overampliﬁcation,
respectively) were used in this study. Both data sets included 889
samples from the TCGA provisional study and were retrieved via cBio
(Cerami et al. 2012).
The discrete copy number calls with samples mapped to those
having gene expression data were used as the covariate to adjust the
CNV effect in the eQTL analysis. The continuous log2 transformed
values were used for assessing the pair-wise correlations and examining
the CNV among samples categorized by the genotype combination of
the identiﬁed SNP pair.
SNP retrieval
We ﬁrst studied the interactions between DLC1 and CDK6 at the
genetic level. SNPs within DLC1 and CDK6, including 10-kb
expansion from both ends, were retrieved using SNPper (Riva and
Kohane 2004). The tagging SNPs were obtained using SNAP (Proxy
Search tool) (Johnson et al. 2008) where Caucasian samples (CEU, i.e.,
northern and western Europe) were included from the 1000 Genomes
Pilot 1, the linkage disequilibrium was restricted to r2 $0.8, and the
distance from the nominal SNP was conﬁned to 500 bp. The retrieved
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SNPs and their tagging SNPs were mapped to HEBCS and POSH
genome-wide association study (GWAS) data, with SNPs present in
both data sets selected for the interaction analysis.
SNP interaction survival analysis
Two factors, age and BRCA status, were considered to be inﬂuential
on patient survival, given the large differences between the average age
of the two cohorts and the crucial roles played by BRCA1/2 and their
potential inﬂuences on patient survival in breast cancer. We adjusted
age (continuous variable) by taking it as a covariate and removed the
confounding effect of BRCA status (binary variable) by taking it as
a covariate and excluding BRCA carriers. Both factors were adjusted
separately and in combination. Additionally, the basic Cox model
without adjusting any factor was built as the reference. In the survival
analysis, additive, dominant, recessive, overdominant (i.e., separating
the heterozygote from the homozygotes in the survival analysis) models
were used to ﬁt each SNP in the pair. The pooled analysis (POOL), i.e.,
data from HEBCS and POSH were pooled together, was conducted to
improve the statistical power in identifying the model that ﬁts both
datasets. Among all the possible combinations (e.g., “dominant+additive”
means ﬁtting the DLC1 SNP to the dominant and the CDK6 SNP to
the additive model), the model having the largest improvement in the
signiﬁcance in the pooled analysis as compared with using HEBCS or
POSH data alone was selected. The interactions were performed between
SNPs of DLC1 and CDK6 using Cox regression model in R (Team
2009).
SNP pairs having a signiﬁcant (P # 0.05) interaction term as
compared with the model without it were ﬁrst selected. Pairs with
hazard ratios (HR) showing a consistent direction between HEBCS
and POSH data sets and improved signiﬁcance in the pooled analysis
were chosen. For each selected interacting SNP pair, the SNP main
effect was analyzed by ﬁtting them, separately, to a Cox regression
model. Analysis using multiple datasets and multiple criteria controls
the false-positive rate of this study.
Linkage disequilibrium checking among SNPs in the
interacting pairs
Linkage disequilibrium (LD) was checked using SNAP (Pairwise LD
tool) (Johnson et al. 2008) for SNPs within the selected pairs, and
redundant pairs sharing the same haplotype (r2 .0.8) were removed.
Default setting was used in SNAP as in the SNP retrieval stage.
Expression quantitative trait loci analysis
The primary solid tumor genotype and level 3 gene expression data
were retrieved from TCGA portal at http://tcga.cancer.gov/dataportal
and used for the expression quantitative trait loci (eQTL) analysis.
TCGA CNV data were retrieved using the cBio cancer genomics
portal (http://www.cbioportal.org/public-portal/) (Cerami et al. 2012)
and was used as the covariate; 502 samples shared the genotype, gene
expression, and CNV data, which were used in the analysis. The
genotype data contain 906,600 SNPs, where genotypes with conﬁdence
score more than 0.1 were considered as missing data (Xu et al. 2009;
Affymetrix 2008). The eQTL analysis was performed with and without
CNV as the covariate.
Expression interaction survival analysis
Gene expression interaction survival analysis was performed between
DLC1 and CDK6 using TCGA data. The gene expression data were
partitioned into binary values (high and low expression) by an
optimized percentile and then ﬁtted into the Cox regression model
including the effect of each gene and their interactions. As a comparison,
the model without the interaction term was built. The signiﬁcance of
the interaction was assessed by the Chi-square test of the likelihood
ratio between the model with and without the interaction term. The
Kaplan-Meier plots on DLC1 expression for tumors overexpressing and
underexpressing CDK6 and those regardless of CDK6 expression were
drawn for each pair.
Protein expression interaction survival analysis was performed
between proteins that directly bind or inﬂuence DLC1 (DLC1 binds
Caveolin 1) (Du et al. 2012), CDK6 (CDK6 binds CDKN1B) (Soos
et al. 1996), and Cyclin D1 (Weinberg 2007) using TCGA RPPA data.
Correlation analysis
Correlation was analyzed at gene expression, protein, and CNV levels.
The spearman correlation scores between each pair were computed
and a linear model was built for each pair as well. The cutoff was set to
P # 0.05 to assess the signiﬁcance of the correlation.
Expression analysis: The gene expression, protein expression, and
CNV proﬁles were checked for the genotype combinations of the
identiﬁed SNP pair. Data at each level were grouped according to the
genotype combination of the SNP pair, and the group-wise pattern
was visualized via boxplot. The signiﬁcance of the heterogeneity across
the distribution of the expression among groups was evaluated by
the Kruskal-Wallis rank sum test, with the null hypothesis being that the
location parameters of the distribution is the same in each group. The
signiﬁcance level was set to P # 0.05 for all the data sets.
Functional tagging SNP exploration: FASTSNP (Yuan et al. 2006)
was used to study the functional roles of the identiﬁed SNPs or
their tagging SNPs. The tagging SNPs being analyzed were retrieved
using SNAP (Proxy Search tool) (Johnson et al. 2008) with r2 .0.8
or d9 .0.8. SNPs located in the coding region and result in missense
mutations or that resided in the intron and cause the loss or addition
of human transcription factors were selected.
RESULTS
Interactions between DLC1 and CDK6
Analysis at the genetic level:We retrieved the SNPs and their tagging
SNPs for DLC1 and CDK6 with r2 .0.8 as described in the Materials
and Methods section. There are 28 DLC1 SNPs and 26 CDK6 SNPs,
respectively, mapped to both the HEBCS and POSH data. A pair-wise
analysis was performed between DLC1 and CDK6 SNPs, resulting in
728 pairs in total. The synergistic effect was found in 14 pairs using all
samples, 10 pairs in ER-negative tumors, and 6 pairs in ER-positive
tumors (the cut-off P value is 0.05; detailed information on SNP pair
selection is presented in the Materials and Methods section) as listed
in Table S2. Among them, only one pair, rs561681 (DLC1) and
rs3731343 (CDK6), shows signiﬁcant associations between each
SNP and the corresponding gene. As shown by the “additive+additive”
models in Table 1, the data ﬁt signiﬁcantly better to the model having
the interaction term as compared with the one that does not, especially
when data from HEBCS and POSH are pooled together (P = 4.96E-11).
Also, the M1 model (model including the interaction term) improves
when ﬁtting the DLC1 SNP to the overdominant model and the CDK6
SNP to the additive model (“overdominant+additive”) rather than
ﬁtting them both to the additive model (“additive+additive”). The
detailed statistics of the selected model (“overdominant+additive” of
M1) were shown in Table S3, where the common and rare alleles of the
Volume 5 January 2015 | DLC1 and CDK6 in Breast Cancer | 83
DLC1 SNP were denoted as “A” and “a” and those for the CDK6 SNP
were represented as “B” and “b”, respectively. It is seen that the
combination of the heterozygote of rs561681 (DLC1) and rare
homozygote of rs3731343 (CDK6) is associated with poorer clinical
outcome (Table S3).
In “Data type,” “SNP” and “GEX” each represent the SNP and gene
expression data, respectively. In “M1+M2,” the name of the genetic
model for each SNP is shown. P (M1) and P (M2) are the P values
of the models M1 and M2, respectively, from the likelihood ratio test,
and P (M1M2) shows the P value of the Chi-square test by comparing
M1 (the model with the interacting term) and M2 (the model without
the interacting term). The “additive+additive” model is the reference null
model, and the “overdominant+additive” model is the selected model.
“SNP” stands for the genotype and phenotype data, “GEX” repre-
sents gene expression data, “PEX” is short for protein expression data,
and “CNV” means copy number variation. The total number of samples
is shown for each data set, and the number of events in data used for
survival analysis is shown in parentheses.
To explore further the signiﬁcance of the interactions of various
genotype combinations on patient survival, the Kaplan Meier plots of
the DLC1 SNP as stratiﬁed by the genotypes of the CDK6 SNP were
drawn (Figure 1), with the statistics summarized in Table 2. It is
shown that the heterozygote of the DLC1 SNP has an amplifying
effect on the CDK6 SNP, i.e., it increases the hazard when combined
with the rare homozygote of the CDK6 SNP (see Figure 1D and com-
pare it with Figure 1C, Table 2) and becomes protective when interact-
ing with the common homozygote of the CDK6 SNP (see Figure 1E
and compare it with Figure 1F, Table 2). Signiﬁcant protective effect
was also observed when ﬁtting both SNPs in the pair to the recessive
model, i.e., neither SNP is rare homozygous (see Figure 1A and com-
pare it with Figure 1B, Table 2). As represented by the stratiﬁcation
analysis (Table 2), this effect, although marginally signiﬁcant in POSH
data (P = 0.097, HR = 0.75, 95% C.I.= 0.53, 1.06), has similar patterns in
both data sets (Figure S1) and the signiﬁcance is largely improved in the
pooled analysis (P = 0.0035, HR = 0.73, 95% C.I. = 0.59, 0.9). This
interaction is signiﬁcant with and without BRCA patients being re-
moved, indicating its independence of BRCA status. Also, whether
the confounding effect of age is adjusted does not make a signiﬁcant
difference here. Importantly, although being less signiﬁcant than inter-
acting with the nonrare homozygote of the CDK6 SNP, the rare ho-
mozygote of the DLC1 SNP signiﬁcantly increases hazard in HEBCS
data and the pooled analysis (Table 2).
The true genotypes are shown under “Genotype,” and the symbols
“A” and “a” represent the common and rare allele in the DLC1 SNP
(rs7654599), and “B” and “b” stand for the common and rare allele
in the CDK6 SNP (rs17213431), respectively, under “Symbol.” P,
HR, and 95% C.I. are the P value, hazard ratio, and 95% conﬁdence
interval (low, high) for each analysis.
The distribution of DLC1 expression signiﬁcantly differs by the
allele distribution of its intronic SNP rs561681 (the P value from the
Kruskal-Wallis rank sum test is 0.023), where DLC1 expression
increases with the dose of the common allele of rs561681 (Figure
2A). Similarly, the distribution of the copy number of DLC1 distinc-
tively varies among patients having different allele combinations of
rs561681 (with a P value from the Kruskal-Wallis rank sum test being
0.00014), and the copy number is most frequently deleted in patients
harboring the rare homozygote of the DLC1 SNP as compared with
the others (Figure 2B). Further, the copy number of DLC1 is signiﬁcantly
positively correlated with that of CDK6 (P = 0.0008, correlation
coefﬁcient is 0.18; Table S4).
We checked the allele frequencies of the identiﬁed SNP pair in the
1000 Genome Project through HapMap (release 27). The allele
frequencies of both alleles in rs561681 are similar, i.e., 41.2% for “a”
and 58.8% for “A,” in CEU (i.e., Utah residents with Northern and
Western European ancestry from the CEPH collection) according to
the 1000 Genome Project (1000 Genomes Project Consortium et al.
2012). For some populations, they can be 50% for each (GBR, i.e.,
England and Scotland) or in an opposite distribution, e.g., 57.1% for
“a” and 42.9% for “A” in CHB (i.e., Chinese in Beijing) (1000
Genomes Project Consortium et al. 2012). The genotype frequencies
of AG (aA) and AA (bb) are 0.54 and 0.195, respectively, in CEU
(1000 Genomes Project Consortium et al. 2012), leading to a frequency
of 10.53% (0.54·0.195) for aA:bb in this population. We also checked
these statistics using our data sets (i.e., HEBCS and POSH, which
belong to the same ethnic group with CEU in the 1000 Genome
Project). As expected, the allele frequencies of rs561681 are 48.35%
(“a”) and 51.58% (“A”) in HEBCS, and 46.42% (“a”) and 54.95% (“A”)
in POSH. The combined genotype aA:bb accounts for 10.32% and
10.87%, respectively, in the HEBCS and POSH data sets (Table 3).
Analysis at the transcriptional level: Signiﬁcant interactions were
also observed between DLC1 and CDK6 at the transcriptional level.
As shown in Table 1, the model improves (P = 6.15E25) and becomes
signiﬁcant (P = 0.00241) when including the interaction term in the
Cox regression model. Poor survival corresponds to low DLC1 and
CDK6 expression (Table 4).
The Kaplan-Meier plots on patient survival regarding DLC1
expression when CDK6 level is low or high and the plot regardless
of CDK6 expression are compared and shown in Figure 3. High
DLC1 expression corresponds to better prognosis when CDK6 is
not particularly high (,74% percentile of all expression, P = 0.003;
Figure 3A), worse survival when CDK6 is high ($74% percentile of all
expression, P = 0.02; Figure 3B), and no survival difference when all
samples were included (P = 0.77; Figure 3C). Similar interactive effects
were also observed in patient survival regarding CDK6 expression as
stratiﬁed by the level of DLC1 (Figure S2).
We next examined the correlations between DLC1 and CDK6
expression. DLC1 was not signiﬁcantly correlated with CDK6
expression when all tumor types were considered (P = 0.0817, corre-
lation = 0.0769) but was signiﬁcantly positively correlated with CDK6
n Table 1 Model selection
Data Type SNP
M1+M2 overdominant+additive recessive+additive dominant+additive additive+additive GEX
Data HEBCS POSH POOL HEBCS POSH POOL HEBCS POSH POOL HEBCS POSH POOL TCGA
P (M1) 0.02 0.205 4.93E212 0.13 0.642 7.02E210 0.561 0.34 1.42E209 0.0489 0.271 4.96E211 0.0024
P (M2) 0.422 0.698 7.57E210 0.201 0.604 2.34E210 0.895 0.956 3.35E209 0.301 0.718 7.50E210 0.9178
P (M1M2) 0.0051 0.0556 2.95E204 0.1436 0.4659 0.2015 0.1907 0.069 0.0269 0.0301 0.0983 0.0029 6.15E-05
M1:G1+G2+G1G2
M2:G1+G2
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in ER-positive tumors (P = 2.18E29, correlation = 0.2967), indicating
the involvement of ER in this interaction.
Analysis of the relevant genes at the translational level: Restricted
by the protein data available for DLC1 and CDK6, we analyzed the
interactive effects of some proteins directly bind to DLC1 or CDK6.
Caveolin 1 binds DLC1, and cyclin D1 and CDKN1B bind CDK6 (Du
et al. 2012; Soos et al. 1996; Weinberg 2007). Signiﬁcant interactions
were observed between caveolin 1 and CDKN1B, as well as between
caveolin 1 and cyclin D1, because the ﬁtness between the data and
model largely improves when the interaction term is included in the
model (Table S5). The statistics of the model including the interaction
term are shown in Table S6. The interactive effect is visualized by the
Kaplan-Meier plots on patient survival using the expression of one
protein as stratiﬁed by the others (Figure S3). Increased hazard
was observed for patients with high caveolin 1 and low CDKN1B
Figure 1 Kaplan Meier plots of patients’ survival showing interactions in the identiﬁed SNP pair between DLC1 and CDK6. The plots were drawn
for the DLC1 SNP (rs561681) stratiﬁed by the genotypes of the CDK6 SNP (rs3731343). Results from HEBCS and POSH data were pooled. Plots
showing (A–B) the interactive effect of AA:AC/CC (aa:bB/BB, the rare homozygote of the DLC1 SNP vs. the combination of the heterozygote and
common homozygote of the CDK6 SNP), (C–D) the interactive effect of AG:AA (aA:bb, the heterozygote of the DLC1 SNP vs. the rare homo-
zygote of the CDK6 SNP), and (E–F) the interactive effect of AG:CC (aA:BB, the heterozygote of the DLC1 SNP vs. the common homozygote of
the CDK6 SNP).
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expression (Figure S3, A and B). Similarly, signiﬁcant favorable prognosis
is associated with patients expressing low cyclin D1 and high caveolin 1
(Figure S3, C and D). None of the three proteins affects patient survival
on its own (Figure S4).
Among all the proteins with RPPA data available in TCGA, 10
proteins, including CDKN1B, PECAM1, p53, Claudin7, CHK1,
Transglutaminase 2, ACC, PRDX1, GSK3, and PKCa, show distinct
protein expression for patients harboring the “aA.bb” genotype com-
bination as compared with the other genotype combinations of the
SNP pair (Table S7, Figure S5). Additionally, caveolin1, experimentally
veriﬁed to bind with DLC1 (Figure S6) (Du et al. 2012), has higher
expression in aA:bb tumors as compared with the others (Figure S5D).
We studied the correlations among proteins directly related
to DLC1 and CDK6 (Figure S6) by the existing experimental data
collected via IPA (Ingenuity Systems, www.ingenuity.com). As
expected, these proteins are signiﬁcantly correlated with each other
(Table S8), and all the input proteins are involved in cellular
development, cellular proliferation, and cell cycle (score 17)
according to IPA.
DISCUSSION
DLC1 interacts with CDK6 in breast cancer
An interaction between DLC1 and CDK6 was found to affect breast
cancer survival. Accordingly, one SNP pair, rs561681 (DLC1) and
rs3731343 (CDK6), was identiﬁed whose nonrare homozygotes
combination (aA/AA:bB/BB) is protective (Table 2). This implies that
both SNPs ﬁt the recessive model and patients without concurrent
n Table 2 Statistics of the SNP pair (rs561681 and rs3731343) representing interactions between DLC1 and CDK6
Genotype HEBCS POSH POOL Meta
Symbol P HR 95% C.I. P HR 95% C.I. P HR 95% C.I. P_HR P_size
AG/GG:CC/AC 0.019 0.72 0.55, 0.95 0.097 0.75 0.53, 1.06 0.0035 0.73 0.59, 0.90 0.0084 0.0076
aA/AA:BB/bB
AG:AA 0.011 1.39 1.08, 1.79 0.059 1.34 0.99, 1.82 0.0016 1.35 1.24, 1.66 0.0032 0.0029
aA:bb
AG:CC 0.004 0.53 0.34, 0.81 0.03 0.57 0.35, 0.95 0.0004 0.56 0.39, 0.76 0.0007 0.0006
aA:BB
AA 0.04 1.3 1.01, 1.67 0.22 1.21 0.89, 1.65 0.016 1.27 1.05, 1.54 0.0362 0.0327
aa
AG 0.13 0.84 0.67, 1.05 0.3 0.87 0.67, 1.13 0.076 0.86 0.72, 1.02 0.1223 0.1144
aA
AA 0.86 1.03 0.78, 1.36 0.88 0.98 0.71, 1.33 0.97 1 0.82, 1.24 0.9445 0.943
bb
CC 0.46 0.91 0.71, 1.17 0.57 1.09 0.82, 1.46 0.91 0.99 0.82, 1.19 0.5248 0.5137
BB
Genotype (Gene): Symbol G (DLC1): A A (DLC1): a
C (CDK6): B A (CDK6): b
Figure 2 Gene expression pattern and copy number variation of DLC1 categorized by the genotypes of the DLC1 SNP (rs561681). (A) Gene
expression pattern categorized by the genotypes of rs561681. (B) Copy number variation categorized by the genotypes of rs561681. The vertical
axis of (A) shows the gene expression value, which is lowess-normalized, followed by log2 transformation of the ratio between two channels, and
that of (B) shows the log2 transformed copy number values from Affymetrix SNP6. Both datasets are retrieved from TCGA.
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mutations in DLC1 and CDK6 may have favorable outcome. This is
conﬁrmed at the transcriptional level because patients without CDK6
overexpression and having excessive DLC1 expression tend to have
better outcome than others (Figure 3A). Further, the allele distribution
of the DLC1 SNP (rs561681) highly correlates with DLC1 expression
(P = 0.004; Table S9). Particularly, the expression increases with the
dose of the common allele (Figure 2A), consistent with the tumor
suppressive role of DLC1. Low copy number of DLC1 is signiﬁcantly
(P = 0.0001) associated with the rare allele of DLC1 (Figure 2B, Table
S9). This is in agreement with the fact that poorer outcome is
associated with the rare allele of DLC1, and DLC1 is frequently
lost in cancer (Qian et al. 2012; Durkin et al. 2007; Kim et al.
2009; Seng et al. 2007). Taken together, the protective effect of
the common allele of the DLC1 SNP is ampliﬁed by the common
allele of the CDK6 SNP. The identiﬁed SNPs both ﬁt the recessive
model, and the association of the rare allele of rs561681 (DLC1)
with poorer clinical outcome is related to or driven by copy
number deletion.
At the protein level, we examined the interactions between
proteins directly related to DLC1 or CDK6. These include caveolin
1 [which directly binds DLC1 (Figure S5) and contributes to its tumor
suppressive roles (Du et al. 2012)], CDKN1B [which is an inhibitor of
and directly binds to CDK6 (Soos et al. 1996)], and cyclin D1 [which
forms a complex with CDK6 (Weinberg 2007)]. Interestingly, the
proteins related to CDK6 signiﬁcantly interact with that of DLC1
at the translational level (Figure S3), additionally supporting the
observed interactions between DLC1 and CDK6 and implying complex
regulatory relationships among these proteins.
DLC1 interacts with CDK6 via a dominant-
negative effect
In the identiﬁed SNP pair, rs561681 (DLC1) ﬁts an overdominant
model in the interactions, i.e., aA:BB is protective and aA:bb is risky.
The heterozygote of the DLC1 SNP exhibits an amplifying effect on the
CDK6 SNP, suggesting a dominant-negative effect of their interactions
at the translational or phenotypic level.
To conﬁrm this hypothesis, we examined the expression of some
related proteins with available data in TCGA. The protein proﬁles
categorized by the genotype combinations of the identiﬁed SNP pair
show distinct patterns for patients having the aA:bb genotype (Figure
S5, Table S7), which are in accordance with their functional roles and
relationships with DLC1 and CDK6, additionally supporting the
dominant-negative interactive effect between DLC1 and CDK6. For
example, CDKN1B directly binds and inhibits CDK6 (known to have
a tumor suppressive role) (Lin et al. 2001; Soos et al. 1996), whose
underexpression implies a poor prognosis. This is consistent with the
increased hazard observed from patients harboring the aA:bb (DLC1:
CDK6) genotype. CDKN1B is regulated by p53 (Abraham et al. 2005),
an important tumor suppressor regulating cell cycle and the guardian
of the genome (Weinberg 2007) that is underexpressed in aA:bb
(DLC1:CDK6) patients. We also checked the genotype distribu-
tion of the DLC1 SNP (rs561681) regarding some important his-
topathological markers (Table S11), among which the amount of
cyclin D1, a binding partner of CDK6, distinctly varies by the
genotypes of rs561681 (P = 0.002) without linear associations with
the allele dose (P = 0.415). This suggests a distinct distribution of
cyclin D1 for aA tumors at the protein level, further supporting
our hypothesis.
Dominant-negative effect has been previously discovered in many
genes and diseases such as Keap1 in lung cancer (Suzuki et al. 2011)
and TNFRSF13B in CVID (common variable immunodeﬁciency)
(Garibyan et al. 2007). The interaction of DLC1 with its substrates
depends on its dimerization and is modulated by the switch from
dimer to monomer mediated by Ser88 phosphorylation (Song et al.
2008). The amino-terminal domain of DLC1 (1-638) is known to have
a dominant-negative effect in blocking cell migration by antagonizing
endogenous DLC1 (Kim et al. 2008). Thus, it is possible that the
variant could produce a dominant-negative mutant that efﬁciently
binds wild-type DLC1 monomers to form heterodimers that are
deﬁcient in its own function but ampliﬁes the effect of CDK6, i.e.,
protective when CDK6 functions normally and risky when CDK6 is
mutated.
The balanced allele distribution of the DLC1 SNP rs561681, as
demonstrated by the statistics from both the 1000 Genome Project
and our data sets, provides the basis for the existence of dominant-
negative mutant in DLC1. However, the dominant-negative effect
revealed using CEU data (our data belong to the CEU ethnic group) is
not driven by the allele distribution, because the combined genotype
aA:bb only accounts for approximately 10% of patients in this
population (both 1000 Genome Project and our datasets) and ranked
in the middle among all the combinations regarding the sample size
(Table 3).
The SNP rs561681 (C_000008.11:g.13093516 by the HGVS name)
is located in the 4th intron of DLC1. One of its tagging SNPs, rs532841
(r2 = 0.652, d9 = 0.955; Table S10), is a missense mutation causing the
amino acid change from valine (V) to methoionine (M) at position
791 (V791M), and the exonic splicing enhancer or silencer (ESE/ESS)
n Table 3 Genotype distribution of the SNPs and their genotype
combinations in HEBCS and POSH data sets
HEBCS POSH
n % n %
DLC1 (rs561681)
GG (AA) 230 28.61 164 30.20
AG (aA) 386 48.01 262 48.25
AA (aa) 188 23.38 117 21.55
CDK6 (rs3731343)
CC (BB) 248 30.85 150 27.62
AC (bB) 397 49.38 261 48.07
AA (bb) 159 19.78 132 24.31
rs561681:rs3731343
GG:CC (AA:BB) 69 8.58 46 8.47
AG:CC (aA:BB) 115 14.30 76 14.00
AA:CC (aa:BB) 64 7.96 28 5.16
GG:AC (AA:bB) 111 13.81 76 14.00
AG:AC (aA:bB) 188 23.38 127 23.39
AA:AC (aa:bB) 98 12.19 58 10.68
GG:AA (AA:bb) 50 6.22 42 7.73
AG:AA (aA:bb) 83 10.32 59 10.87
AA:AA (aa:bb) 26 3.23 31 5.71
n Table 4 Statistics of the selected model including the interactions
between DLC1 and CDK6 at the transcriptional level
Gene Level HR 95% C.I.
DLC1 Low (,74%) 0.18 0.29, 0.92
CDK6 Low (,50%) 0.36 0.09, 0.72
DLC1:CDK6 low:low 10.93 3.06, 38.98
Gene shows the gene and gene pair. Level shows the expression level, with
the expression percentile shown in parentheses. HR and 95% C.I. are the
hazard ratio and 95% conﬁdence interval (low, high) for each gene or gene pair,
respectively.
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motif is predicted to be changed using FASTSNP (Yuan et al. 2006).
Another mutation of R718E was reported to result in a dominant-
negative mutant in DLC1 due to the loss of the catalytic function in
the RhoGAP domain (609–878) and the retain of the tensin binding
site (Tyr442) (Kim et al. 2008). Because V791M is closely located
around R718E, it is possible that a dominant-negative mutant is gen-
erated from the same mechanism here. However, another tagging SNP
rs621554 (r2 = 0.817, d9=1; Table S10) causes the loss of the binding
sites of transcription factors AP1 and CREB according to FASTSNP
(Yuan et al. 2006). Besides rs621554, 91 tagging SNPs are located in
the human transcription factor binding sites in the intron of DLC1
(Table S12). Apart from AP1 (Tu et al. 2009; Lu et al. 2002; van der
Burg et al. 1995) and CREB (Conkright and Montminy 2005; Pradeep
et al. 2004; Ionov et al. 2004; Jean and Bar-Eli 2001), the most
frequently varied binding sites also include GATA1, GATA2, and
GATA3, which are essential in cell-cycle control whose alteration
contributes to the tumorigenesis process (Friedman 2010; Rylski
et al. 2003; Kumar et al. 2012; Wang et al. 2012; Jacquemier et al.
2009; Ciocca et al. 2009; Abba et al. 2006; Mehra et al. 2005). These
reports are suggestive and supportive of our hypothesis that the rare
allele of rs561681 could reduce DLC1 expression by changing the
binding sites of transcription factors such as AP1 and CREB, and
the heterodimer produced by the heterozygote (aA) ampliﬁes the
effect of CDK6. However, the exact mechanism needs further in-depth
exploration.
Interactions between DLC1 and cell-cycle genes are
inﬂuenced by ER status in breast cancer
The gene expression of DLC1 is positively inﬂuenced by that of CDK6
in ER-positive breast tumors (Table S13), indicating the importance of
ER in the interactions between DLC1 and CDK6 in breast cancer. It is
reported that DLC1 directly interacts with liganded ER and facilitates
estrogen-induced ER transactivation and anchorage-independent cell
growth (Rayala et al. 2005); also, DLC1 expression leads to enhanced
recruitment of DLC1-ER complex to the ER-target gene chromatin,
and estrogen induces the transcription and expression of DLC1
(Rayala et al. 2005). Some genes interacting with DLC1 or CDK6
are known to cooperate with ER as well. For example, cyclin D
[which forms a complex with CDK4/6 (Weinberg 2007)] was suggested
to operate upstream of ER (Neuman et al. 1997) and to enhance
transactivation through an estrogen response element in a CDK-
independent manner (Zwijsen et al. 1997; Neuman et al. 1997), whose
overexpression was shown to correlate with an ER-positive status in
breast cancer (Fantl et al. 1990; Courjal et al. 1996; Buckley et al. 1993).
Figure 3 Kaplan Meier plots of patients’ survival showing interactions between DLC1 and CDK6 gene expression. (A) Kaplan Meier plots on
patient survival for DLC1 gene expression when the expression level of CDK6 is less than the 74% percentile of all the samples. (B) Kaplan Meier
plots of patient survival for DLC1 gene expression when the expression level of CDK6 is no less than 74% percentile of all the samples. (C) Kaplan
Meier plots of patient survival for DLC1 gene expression when all samples are included. Median was used to split the gene expression of CDK6
into high and low expressions in both subplots.
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Finally, Figure S5 shows the current experimentally veriﬁed connec-
tions among the genes with interest from various tissues or cell lines
collected in IPA. Given the heterogeneity of breast cancer and the
important roles of ER in breast tumor subtype classiﬁcation (Blows
et al. 2010), ER may have a more intimate connection with these genes
in breast cancer. We believe the involvement of ER in the synergistic
effect between DLC1 and CDK6 could be revealed given datasets of
larger sample size and more ethnic groups.
CONCLUSION
The interactions between DLC1 and CDK6 were detected and
explored at the genetic level and conﬁrmed at the transcriptional
level. Interactions of relevant proteins at the translational level provide
additional evidence supporting the interactions between DLC1 and
CDK6 and imply a complex regulatory relationship among them. In
particular, one SNP pair, rs561681 (DLC1) and rs3731343 (CDK6),
was identiﬁed to have a synergistic effect on breast cancer patient
survival, as veriﬁed in two independent cohorts, and these SNPs were
each associated with the expression of the corresponding gene. The
interaction between the nonmutant forms of the two SNPs is
protective. The DLC1 SNP (rs561681) ﬁts a recessive model, complying
with the tumor suppressive role of DLC1. Tumors that are rare
homozygous for the DLC1 SNP (rs561681) exhibit lower gene
expression and more frequent copy number loss of DLC1. Signiﬁcant
survival differences were observed on DLC1 expression as stratiﬁed by
that of CDK6, with more favorable prognosis for patients without
CDK6 overexpression and high DLC1 level. In addition, the protein
that directly binds to DLC1 (i.e., caveolin 1) was shown to have
signiﬁcant interactive effects with those related to CDK6 (i.e., cyclin
D1 and CDKN1B), further suggesting the interactions observed
between the genes of interest.
The interaction between the proteins DLC1 and CDK6 was shown
to have a dominant-negative effect, as suggested by the signiﬁcant
risky effect of aA:bb and protective effect of aA:BB of the identiﬁed
SNP pair. Several related proteins show distinct patterns for tumors
having the aA:bb genotype combination. This evidence suggests
that the DLC1 heterodimers (gene product of aA) adversely affect
the wild-type homodimers (products of AA), resulting in a poorer
prognosis than the mutant homodimers (the product of aa). In other
words, DLC1 expression is the lowest in rare homozygous patients
(aa), and that of functional DLC1 is the lowest in patients harboring
aA:bb among all the genotype combinations.
In this study, we have linked the germline genetic polymorphisms
and their synergistic effect with breast cancer progression, which
provides the basis for experimentally elucidating the mechanisms
involved in differential progression. The ﬁndings are particularly
useful in investigating inherited susceptibility and their cooperative
roles in tumor progression, with the ultimate goal of tailoring
clinical treatments for breast cancer patients based on their genetic
susceptibility.
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